SHSE:688443 (China)
Â
Ordinary Shares - Class A
Â¥
28.35
(-0.56%)
Nov 29
Business Description
Chongqing Genrix Biopharmaceutical Co Ltd
ISIN : CNE100006KG8
Share Class Description:
SHSE:688443: Ordinary Shares - Class ACompare
Compare
Traded in other countries / regions
688443.China IPO Date
2023-06-20Description
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.35 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.33 | |||||
| Debt-to-EBITDA | -1.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.57 | |||||
| Beneish M-Score | 72.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | 24.88 | |||||
| Future 3-5Y Total Revenue Growth Rate | 657.99 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.61 | |||||
| 9-Day RSI | 50.96 | |||||
| 14-Day RSI | 50.63 | |||||
| 6-1 Month Momentum % | -28.49 | |||||
| 12-1 Month Momentum % | -26.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.02 | |||||
| Quick Ratio | 18.62 | |||||
| Cash Ratio | 17.74 | |||||
| Days Inventory | 7011.53 | |||||
| Days Sales Outstanding | 124.13 | |||||
| Days Payable | 9466.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 1.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.45 | |||||
| Operating Margin % | -6062.76 | |||||
| Net Margin % | -5748.36 | |||||
| FCF Margin % | -4212.48 | |||||
| ROE % | -29.4 | |||||
| ROA % | -22.44 | |||||
| ROIC % | -140.98 | |||||
| ROC (Joel Greenblatt) % | -149.46 | |||||
| ROCE % | -22.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 766.22 | |||||
| PB Ratio | 4.42 | |||||
| Price-to-Tangible-Book | 4.5 | |||||
| EV-to-EBIT | -11.52 | |||||
| EV-to-EBITDA | -11.52 | |||||
| EV-to-Revenue | 638.59 | |||||
| EV-to-FCF | -13.89 | |||||
| Price-to-Net-Current-Asset-Value | 5.72 | |||||
| Price-to-Net-Cash | 6.37 | |||||
| Earnings Yield (Greenblatt) % | -8.68 | |||||
| FCF Yield % | -5.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chongqing Genrix Biopharmaceutical Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 13.559 | ||
| EPS (TTM) (Â¥) | -2.13 | ||
| Beta | 0 | ||
| Volatility % | 53.8 | ||
| 14-Day RSI | 50.63 | ||
| 14-Day ATR (Â¥) | 1.889236 | ||
| 20-Day SMA (Â¥) | 28.853 | ||
| 12-1 Month Momentum % | -26.39 | ||
| 52-Week Range (Â¥) | 22.11 - 45.51 | ||
| Shares Outstanding (Mil) | 366.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chongqing Genrix Biopharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chongqing Genrix Biopharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chongqing Genrix Biopharmaceutical Co Ltd Frequently Asked Questions
What is Chongqing Genrix Biopharmaceutical Co Ltd(SHSE:688443)'s stock price today?
The current price of SHSE:688443 is ¥28.35. The 52 week high of SHSE:688443 is ¥45.51 and 52 week low is ¥22.11.
When is next earnings date of Chongqing Genrix Biopharmaceutical Co Ltd(SHSE:688443)?
The next earnings date of Chongqing Genrix Biopharmaceutical Co Ltd(SHSE:688443) is .
Does Chongqing Genrix Biopharmaceutical Co Ltd(SHSE:688443) pay dividends? If so, how much?
Chongqing Genrix Biopharmaceutical Co Ltd(SHSE:688443) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers